



November 13, 2019

Via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Notice Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. ("Teva") submits this information pursuant to 18 V.S.A. § 4637(b). On November 11, 2019 Teva released the following prescription drug to the commercial market:

NDC #	Product	WAC	Commercial Launch Date
63459-0103-10	TRUXIMA® (rituximab-abbs) 100 MG / 10 ML	\$845.55	11/11/2019
63459-0104-50	TRUXIMA® (rituximab-abbs) 500 MG / 50 ML	\$ 4,227.75	11/11/2019

Teva provides this notice consistent with its understanding and interpretation of 18 V.S.A. § 4637 and its provisions. In providing this notice, Teva does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Teva or any of its affiliates, now or in the future. Teva, on behalf of itself and its affiliates, expressly reserves all such rights.

Sincerely,

DocuSigned by:
Katie Hiett
A9CAB028546F4BF...

Katie Hiett
SVP, Strategic Pricing, Contracting & Customer Operations
Teva Pharmaceuticals USA, Inc.